Primary Care for Transgender Women

On this page

Foundations & Initial Assessment - Trans Welcome Wagon

  • Key Terms:
    • Gender Identity: Internal sense of self.
    • Gender Dysphoria: Distress from gender incongruence.
    • Affirming Language: Crucial; use chosen name/pronouns.
  • Initial Steps:
    • Create a safe, respectful, confidential space.
    • Comprehensive history: medical, mental health (screen for anxiety/depression), social support, substance use.
    • Clarify transition goals & expectations.
    • Initiate informed consent process.
    • Assess for risks (e.g., STIs, HIV).

⭐ Documenting gender identity, chosen name, and pronouns accurately in medical records is a critical first step for affirming care and patient safety.

Feminizing Hormone Therapy - Estrogen Engine Start

  • Goal: Induce female secondary traits, suppress male ones.
  • Estrogen Options:
    • Oral: Estradiol 2-6 mg/day.
    • Transdermal (patch/gel): Estradiol 0.05-0.2 mg/day. Preferred if ↑VTE risk.
    • Parenteral (IM): Estradiol valerate/cypionate 5-20 mg q2wks or 2-5 mg qwk.
  • Anti-Androgens:
    • Spironolactone: 100-300 mg/day (monitor K+).
    • Cyproterone Acetate (CPA): 12.5-25 mg/day (monitor LFTs, prolactin).
    • GnRH Agonists: Most potent.
  • Monitoring (q3mo for 1yr, then annually):
    • Estradiol: Target 100-200 pg/mL.
    • Testosterone: Target <50 ng/dL.
  • Timeline: Breast growth (3-6mo), fat redistribution (3-6mo), ↓libido (1-3mo).

Timeline of physical changes with feminizing hormones

⭐ Transdermal estrogen carries a lower VTE risk than oral forms, crucial for patients with higher baseline VTE risk.

Health Maintenance & Screening - Femme Health Checkpoint

  • Cardiovascular: Monitor BP, lipids, glucose. Estrogen ↑ VTE risk.
  • Bone Health: DEXA if risk factors (e.g., GnRH agonist, low BMI, fracture history).
  • Cancer Screening:
    • Breast: Mammography age 50-74 (or earlier if >5-10 yrs estrogen/risk factors).

    ⭐ Transgender women on long-term estrogen therapy (typically >5 years) should follow breast cancer screening guidelines similar to cisgender women.

    • Prostate: Discuss PSA if prostate present, age >50 & risk factors.
    • Anal: Consider for anal receptive intercourse.
  • Hormone Levels: Estradiol, testosterone, prolactin. Monitor LFTs.
  • Mental Health: Screen for depression, anxiety.

Managing Complications & Special Issues - Side Effect Surfing

  • VTE (Estrogen): Counsel (DVT/PE symptoms). Prefer transdermal (↓risk). Assess individual risk factors.
  • Hyperkalemia (Spironolactone): Monitor K+ (esp. renal disease, ACEi/ARBs). Dietary advice.
  • Mood Changes (Estrogen/Anti-androgens): Validate. Differentiate. Consider dose/agent adjustment.
  • Hepatotoxicity (CPA): Monitor LFTs. Discontinue if significant ↑.
  • Other common: Weight gain (lifestyle), ↓libido (discuss expectations), breast tenderness (reassurance).

⭐ Transdermal estrogen is associated with a lower risk of VTE compared to oral estrogen in transgender women.

High‑Yield Points - ⚡ Biggest Takeaways

  • Feminizing hormone therapy: Estrogen (oral/transdermal) plus anti-androgens (e.g., spironolactone).
  • Monitor: VTE risk (↑ with oral estrogen), lipids, prolactin, potassium (spironolactone), liver function.
  • Cancer screening: Breast (mammography), prostate (if present), cervical (if cervix present).
  • Regular cardiovascular risk assessment and bone density screening (DEXA) are vital.
  • Address mental health (depression, anxiety), sexual health (STIs), and fertility preservation pre-therapy.
  • Ensure routine health maintenance, including vaccinations, tailored to anatomy and risk factors.
Rezzy AI Tutor

Have doubts about this lesson?

Ask Rezzy, our AI tutor, to explain anything you didn't understand

Practice Questions: Primary Care for Transgender Women

Test your understanding with these related questions

Which of the following statements about the benefits of hormone replacement therapy is incorrect?

1 of 5

Flashcards: Primary Care for Transgender Women

1/7

The patient should not have intercourse _____ hours prior to performing a pap smear

TAP TO REVEAL ANSWER

The patient should not have intercourse _____ hours prior to performing a pap smear

24

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start For Free